Our teams have a track record of excellence in drug discovery and development from drug design, hit generation, hit-to-lead, lead selection and optimization in various therapeutic areas including antisense therapies and therapies targeting kinases, microtubule polymerization, polymerases, reverse transcriptase, nucleic acids, tat, various GPCR’s, and other key enzymes.
Granlen offers a fully integrated pre-clinical development program. We use high-throughput techniques, draw on a long history of small-molecule research, and use modern synthetic techniques to rapidly provide new candidates for testing. Our medicinal chemistry team has experience with CNS, oncology, antivirals, anti-infectives, as well as metabolic disorders including obesity, dyslipidemia, and diabetes. Our world-class scientists have a proven track record working with pharmaceutical and biotechnology companies and have helped lead a number of drug candidates into clinical trials.
Our experienced team has led a full range of drug development activities including formulation, CMC, drug quality and stability studies, as well as IND documentation, application and approval.
Our executives have led the discovery and development of:
• An anti-mitotic drug (currently in Phase II)
• An HBV drug (currently in Phase III)
• An HIV drug (NNRTI, currently in Phase I)
• An anticancer drug (kinase inhibitor, currently in Phase I)
• An anti-atherosclerosis drug ( LXR-beta agonist, currently in Phase I)
• An HIV drug (RT inhibitor, IND stage)
• An anti-hypertension drug candidate (MR antagonist, IND stage), and
• An HCV drug candidate (IND stage)